No­var­tis, Io­n­is will work to­geth­er again in the next-gen­er­a­tion car­dio space

No­var­tis is once again team­ing up with Io­n­is on a next-gen­er­a­tion siR­NA car­dio drug, pick­ing up an­oth­er shot in an in­creas­ing­ly com­pet­i­tive space.

The deal cen­ters around car­dio­vas­cu­lar dis­ease dri­ven by lipopro­tein(a), or Lp(a), a fat-trans­port mol­e­cule that is es­ti­mat­ed to in­crease CVD risk by 20% to 30% of the glob­al pop­u­la­tion. Io­n­is will get $60 mil­lion in up­front cash for the as-yet un­named drug, and will be el­i­gi­ble for an undis­closed amount of mile­stone pay­ments, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER